![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
A more recent version of this article appeared on January 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 17, 2002
Revised on August 21, 2002
Accepted on September 30, 2002
1 Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, North Carolina, 27157
* Corresponding author. E-mail address: athorbur{at}wfubmc.edu.
The adapter protein FADD consists of two protein interaction domains-a death domain and a death effector domain. The death domain binds to activated death receptors such as Fas while the death effector domain binds to pro-caspase 8. A FADD mutant, which consists of only the death domain (FADD-DD), inhibits death receptor-induced apoptosis. FADD-DD can also activate a mechanistically distinct, cell type-specific apoptotic pathway that kills normal but not cancerous prostate epithelial cells. Here, we show that this apoptosis occurs through activation of caspases 9, 3, 6 and 7 and a serine protease. Simultaneous inhibition of caspases and serine proteases prevents FADD-DD-induced death. Inhibition of either pathway alone does not prevent cell death but does affect the morphology of the dying cells. Normal prostate epithelial cells require both the caspase and serine protease inhibitors to efficiently prevent apoptosis in response to TRAIL. In contrast, the serine protease inhibitor does not affect TRAIL-induced death in prostate tumor cells suggesting that the FADD-DD-dependent pathway can be activated by TRAIL. This apoptosis pathway is activated in a cell type-specific manner that is defective in cancer cells suggesting that this pathway may be targeted during cancer development.
This article has been cited by other articles:
|
|
 |
|
  R. V. Warke, K. J. Martin, K. Giaya, S. K. Shaw, A. L. Rothman, and I. Bosch TRAIL Is a Novel Antiviral Protein against Dengue Virus J. Virol., January 1, 2008; 82(1): 555 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhu, J. Chen, X. Cong, S. Hu, and X. Chen Hypoxia and Serum Deprivation-Induced Apoptosis in Mesenchymal Stem Cells Stem Cells, February 1, 2006; 24(2): 416 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Song and C. O. Jacob The Mouse Cell Surface Protein TOSO Regulates Fas/Fas Ligand-induced Apoptosis through Its Binding to Fas-associated Death Domain J. Biol. Chem., March 11, 2005; 280(10): 9618 - 9626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Thorburn, F. Moore, A. Rao, W. W. Barclay, L. R. Thomas, K. W. Grant, S. D. Cramer, and A. Thorburn Selective Inactivation of a Fas-associated Death Domain Protein (FADD)-dependent Apoptosis and Autophagy Pathway in Immortal Epithelial Cells Mol. Biol. Cell, March 1, 2005; 16(3): 1189 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Kalli, K. E. Devine, M. C. Cabot, C. R. Arnt, M. P. Heldebrant, P. A. Svingen, C. Erlichman, L. C. Hartmann, C. A. Conover, and S. H. Kaufmann Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines Mol. Pharmacol., December 1, 2003; 64(6): 1434 - 1443. [Abstract] [Full Text] [PDF]
|
|
